DURESTA Trademark

Trademark Overview


On Wednesday, December 6, 2017, a trademark application was filed for DURESTA with the United States Patent and Trademark Office. The USPTO has given the DURESTA trademark a serial number of 87710776. The federal status of this trademark filing is ABANDONED - EXPRESS AFTER PUB as of Thursday, December 17, 2020. This trademark is owned by Allergan Sales, LLC. The DURESTA trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations used in connection with anti-aging, namely, for use in the treatment of glabellar lines, facial wrinkles, asymmetries and defects and conditions of the human skin, and for facial aesthetic surgery, facial aesthetic reconstruction, and breast aesthetic treatment procedures; pharmaceutical preparations for the treatment of migraines; topical antibiotics, anti-inflammatory, anti-infective, anti-glaucoma agents and decongestant formulations; sterile antibiotic ointments; ocular wetting solutions, artificial tears and pharmaceutical preparations for the treatment of minor ocular inflammations and allergic conditions; Pharmaceutical preparations for the treatment of neurological disorders, muscle dystonias, smooth muscle disorders, autonomic nerve disorders, headaches, hyperhydrosis, sports injuries, cerebral palsy, spasms, tremors and pain; dermatological formulations, namely, medicated dry skin lotions and creams, acne medications and medicated skin lightener lo...
duresta

General Information


Serial Number87710776
Word MarkDURESTA
Filing DateWednesday, December 6, 2017
Status605 - ABANDONED - EXPRESS AFTER PUB
Status DateThursday, December 17, 2020
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, April 17, 2018

Trademark Statements


Goods and ServicesPharmaceutical preparations used in connection with anti-aging, namely, for use in the treatment of glabellar lines, facial wrinkles, asymmetries and defects and conditions of the human skin, and for facial aesthetic surgery, facial aesthetic reconstruction, and breast aesthetic treatment procedures; pharmaceutical preparations for the treatment of migraines; topical antibiotics, anti-inflammatory, anti-infective, anti-glaucoma agents and decongestant formulations; sterile antibiotic ointments; ocular wetting solutions, artificial tears and pharmaceutical preparations for the treatment of minor ocular inflammations and allergic conditions; Pharmaceutical preparations for the treatment of neurological disorders, muscle dystonias, smooth muscle disorders, autonomic nerve disorders, headaches, hyperhydrosis, sports injuries, cerebral palsy, spasms, tremors and pain; dermatological formulations, namely, medicated dry skin lotions and creams, acne medications and medicated skin lightener lotions and creams; Oral, transdermal, injectable and intravaginal contraceptive preparations; intravaginal contraceptive sponge; Hormone replacement therapy preparations; Pharmaceutical preparations for the prevention of preterm birth or pregnancy; Pharmaceutical preparations for the treatment and prevention of urinary incontinence and overactive bladder; Pharmaceutical preparations for the treatment and prevention of iron deficiency and anemia; Pharmaceutical preparations for the treatment and prevention of osteoporosis; Pharmaceutical preparations for the treatment and prevention of endometriosis; Pharmaceutical preparations for the treatment and prevention of symptoms associated with uterine fibroids; Iron chelating pharmaceutical preparations; Fertility enhancing pharmaceutical preparations; Pharmaceutical preparations and medicines for the treatment and prevention of sexual dysfunction; Pharmaceutical preparations and medicines for the treatment of sensory organ disorders; Pharmaceutical preparations and medicines for the treatment of central nervous system disorders; Pharmaceutical preparations and medicines for the treatment of urogenital organ disorders; Pharmaceutical preparations and medicines for the treatment of circulatory system disorders; Pharmaceutical preparations and medicines for the treatment of cardiovascular and blood pressure; Pharmaceutical preparations for the treatment and prevention of digestive tract, gastrointestinal and dermatological diseases and disorders; Pharmaceutical preparations and medicines for the treatment and prevention of irritable bowel syndrome; Pharmaceutical preparations that support, encourage or promote bone strength or bone health or which are used in the treatment of bone disorders or bone diseases; Antibiotics; Antifungal preparations; Antivirals and Antiprotozoals; Pharmaceutical preparations for the prevention and treatment of bacterial infections; Pharmaceutical preparations for the prevention and treatment of diabetes and diabetic neuropathy; Pharmaceutical preparations for the prevention and treatment of pain and neuropathic pain; Pharmaceutical preparations for the prevention and treatment of respiratory system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of neurological diseases and disorders; Pharmaceutical preparations for the prevention and treatment of neurodegenerative diseases and disorders; Pharmaceutical preparations for the prevention and treatment of peripheral nervous system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of hypertension; Pharmaceutical preparations for the prevention and treatment of Alzheimer's disease, dementia, AIDS-related dementia, central nervous system (CNS) disorders, neurological disorders, neurodegenerative disorders, and depression; neuroprotective agent; antidepressants; pharmaceuticals, namely, antipsychotics; coronary vasodilating agents; Pharmaceutical preparations for the treatment of hypothyroidism; Pharmaceutical and cosmeceutical preparations for skin care, namely, medicated skin cleansers, toners, moisturizers, rejuvenators, rehydrating creams, and lotions for the face and body

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code8 - Abandoned
Class Status DateThursday, December 17, 2020
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameAllergan Sales, LLC
Party Type20 - Owner at Publication
Legal Entity Type16 - Limited Liability Company
AddressMadison, NJ 07940

Party NameAllergan Sales, LLC
Party Type10 - Original Applicant
Legal Entity Type16 - Limited Liability Company
AddressMadison, NJ 07940

Trademark Events


Event DateEvent Description
Thursday, December 17, 2020ABANDONMENT NOTICE E-MAILED - AFTER PUBLICATION
Thursday, December 17, 2020ABANDONMENT - AFTER PUBLICATION
Wednesday, December 16, 2020TEAS EXPRESS ABANDONMENT RECEIVED
Friday, December 4, 2020TEAS EXTENSION RECEIVED
Saturday, May 30, 2020NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, May 28, 2020EXTENSION 4 GRANTED
Thursday, May 28, 2020EXTENSION 4 FILED
Thursday, May 28, 2020TEAS EXTENSION RECEIVED
Tuesday, December 10, 2019NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, December 6, 2019EXTENSION 3 GRANTED
Friday, December 6, 2019EXTENSION 3 FILED
Friday, December 6, 2019TEAS EXTENSION RECEIVED
Tuesday, March 19, 2019NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, March 15, 2019EXTENSION 2 GRANTED
Friday, March 15, 2019EXTENSION 2 FILED
Friday, March 15, 2019TEAS EXTENSION RECEIVED
Saturday, November 3, 2018NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, November 1, 2018EXTENSION 1 GRANTED
Thursday, November 1, 2018EXTENSION 1 FILED
Thursday, November 1, 2018TEAS EXTENSION RECEIVED
Tuesday, June 12, 2018NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, April 17, 2018OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, April 17, 2018PUBLISHED FOR OPPOSITION
Wednesday, March 28, 2018NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Wednesday, March 14, 2018APPROVED FOR PUB - PRINCIPAL REGISTER
Tuesday, March 13, 2018ASSIGNED TO EXAMINER
Sunday, December 17, 2017NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Saturday, December 9, 2017NEW APPLICATION ENTERED IN TRAM